As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy

As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy

Source: 
Xconomy
snippet: 

The race to use gene therapy to treat Duchenne muscular dystrophy, a progressive, deadly genetic disease that affects boys, is heating up this week. The FDA just cleared Solid Biosciences to resume clinical testing of a Duchenne gene therapy, a day before Sarepta Therapeutics will report human clinical data from a rival treatment that also uses the approach.